Fluralaner
![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌflʊərəˈlænər/ FLOOR-ə-LAN-ər |
Trade names | Bravecto, Exzolt |
Other names |
|
License data |
|
Routes of administration | By mouth |
ATCvet code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 20–27%;[9] reduced in the fasted state[10] |
Elimination half-life | 9.3–16.2 days[11] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.215.812 |
Chemical and physical data | |
Formula | C22H17Cl2F6N3O3 |
Molar mass | 556.29 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
|
Fluralaner, (INN)[12] sold under the brand name Bravecto among others, is a systemic insecticide and acaricide that is administered orally[13] or topically.[14] The US Food and Drug Administration (FDA) approved it for flea treatment in dogs in May 2014,[15] and approved the combination fluralaner/moxidectin (Bravecto Plus) as a topical treatment for cats in November 2019.[16][17][18][19] The EU approved fluralaner in March 2014.[5][6][20] Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015.[21] For treating mites in chickens, a solution for use in drinking water is available under the brand name Exzolt[22] and was approved for use in the EU in 2017.[23]
Mode of action
Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABAA receptors) and L-glutamate-gated chloride channels (GluCls).[24] Potency of fluralaner is comparable to fipronil (a related GABA-antagonist insecticide and acaricide).[25]
Research
Fluralaner is being investigated to determine its ability to reduce the incidence of mosquito-borne diseases,[26] as well as bed bugs.[27][28]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.